Annals of Urologic Oncology (AUO, Ann Urol Oncol, p-ISSN: 2617-7765, e-ISSN: 2617-7773) publishes the results of novel research in the laboratory and clinical settings, including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human urologic oncology with the overall goal of improving clinical care of patients with urologic tumours. In the journal, it includes three main subjects: bladder, prostate and kidney cancer. In addition, adrenal tumor, testicular cancer, and carcinoma of penis are also considered for the journal subjects.
AUO subscribes fully to the COPE code of conduct and best practice for journal editors ensuring that our editors are accountable for everything published in our journal. Our readers will always be informed about how the research is funded and our relationships with authors, reviewers and editorial board members will be influenced by COPE recommendations.
Peng Zhang (Asian Medical Press Ltd)
Contact: Peng Zhang
Tel: +86-18164057850
Email: monkeyzhangpeng@hotmail.com
Published By
The journal is published by Asian Medical Press Ltd.
Submissions to AUO are made using self-developed Manuscript System to proceed the online submission and peer review system. The website of Registration and access is http://em.asmepress.com/.
All Manuscripts submitted to the Journal should be original achievement presenting previously unpublished data or interpretations; they should not be submitted elsewhere while under editorial consideration. Manuscripts should be clear and credible in argument, and there is a clear hierarchy, with concise headings, an appropriate mix of text, figures and tables.
Each author must disclose all financial relationships related to the paper topic. It should include equity ownership, profit-sharing agreements, royalties, patents, and grants. It is no necessary for authors to report the sums concerned, and to state “none” if none.